Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Michael O'Riordan

June 25, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

Michael O'Riordan

January 10, 2017

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Less Is More: Lp(a) Much More Atherogenic Than LDL

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Recurrent Events Common Among Young Patients With CAD

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

No Need for Niacin? Meta-analysis Argues the End Is Nigh

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content